Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.6 million.

  • Ptc Therapeutics' Other Non-Current Liabilities fell 88.28% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 88.28%. This contributed to the annual value of $21.4 million for FY2024, which is 40.98% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Other Non-Current Liabilities of $2.6 million as of Q3 2025, which was down 67.04% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Other Non-Current Liabilities ranged from a high of $252.0 million in Q3 2021 and a low of $2.6 million during Q3 2025.
  • In the last 3 years, Ptc Therapeutics' Other Non-Current Liabilities had a median value of $22.4 million in 2025 and averaged $37.5 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first increased by 7.65% in 2021, then slumped by 88.28% in 2025.
  • Ptc Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $239.9 million in 2021, then crashed by 31.64% to $164.0 million in 2022, then plummeted by 77.87% to $36.3 million in 2023, then tumbled by 40.98% to $21.4 million in 2024, then slumped by 88.28% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $7.8 million for Q2 2025, and $22.4 million during Q1 2025.